Published in Medical Letter on the CDC and FDA, April 26th, 2009
PromactaŽ (eltrombopag) was granted accelerated approval by the U.S. Food and Drug Administration in November 2008 for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA